m-(Trifluoromethyl)benzyl tert-butyl ether | 72390-17-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: m-(Trifluoromethyl)benzyl tert-butyl ether
• 英文别名: 1-[(2-methylpropan-2-yl)oxymethyl]-3-(trifluoromethyl)benzene
• CAS: 72390-17-1
• 化学式: C₁₂H₁₅F₃O
• 分子量: 232.246
• InChiKey: NCCFXTKTFKFTGR-UHFFFAOYSA-N

物化性质

• 沸点：
  214.7±35.0 °C(Predicted)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-三氟甲基苯甲醇 、 叔丁醇 在 硫酸 作用下， 反应 168.0h， 以51%的产率得到m-(Trifluoromethyl)benzyl tert-butyl ether
  参考文献：
  名称：

  Photochemcial transformations. 26. Sensitized and unsensitized photoreactions of some benzyl chlorides in tert-butyl alcohol

  摘要：

  DOI：

  10.1021/jo01294a007

文献信息

• GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE
  申请人：SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

  公开号：US20210115082A1

  公开（公告）日：2021-04-22

  The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

  本发明公开了一种由III式表示的糖苷化合物，以及其制备方法、组合物、用途和中间体。本发明提供的糖苷化合物具有简单的制备方法，可以显著增加VEGF-A mRNA的表达，并且在促进血管生成方面具有有效性。这为开发具有促血管生成活性的药物治疗脑梗死、脑卒中、心肌梗死和下肢缺血微循环障碍提供了可靠的保证。
• Hsp70 modulators and methods for making and using the same
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US10647683B2

  公开（公告）日：2020-05-12

  The present invention, among other things, provides compounds and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.

  除其他外，本发明提供了用于调节 Hsp70 的化合物及其组合物。在一些实施方案中，本发明提供了一种抑制 Hsp70 活性的方法。在一些实施方案中，本发明提供了一种治疗患有或易患对Hsp70抑制有反应的疾病、紊乱或状况的受试者的方法，包括给受试者施用治疗有效量的所提供的化合物。在一些实施方案中，本发明提供了一种治疗或预防癌症患者的方法，包括向有需要的患者施用治疗有效量的所提供的化合物。
• Glutamine transport inhibitors and methods for treating cancer
  申请人：Vanderbilt University

  公开号：US10793514B2

  公开（公告）日：2020-10-06

  The present disclosure provides compounds of formula: wherein R1, R2, and n are defined as set forth in the specification, and related aminobutanoic acids. The present disclosure also provides compositions comprising these compounds and methods for modulating ASCT2 function in a patient in need thereof.

  本公开提供了式化合物： 其中 R1、R2 和 n 的定义如说明书所述，以及相关的氨基丁酸。本公开还提供了包含这些化合物的组合物，以及在有需要的患者中调节 ASCT2 功能的方法。
• Small molecule antagonists of sumo related modification of CRMP2 and uses thereof
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US11208397B2

  公开（公告）日：2021-12-28

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

  本发明属于药物化学领域。特别是，本发明涉及一类具有哌啶基苯并咪唑结构的新的小分子，它们可作为塌缩素反应介质蛋白 2（CRMP2）的小泛素样修饰剂（SUMO）相关修饰（SUMOylation）的拮抗剂，并可用作治疗与电压门控钠通道 1.7（Nav1.7）相关的痒、嗅觉障碍、偏头痛事件和/或疼痛（如神经性疼痛）的药物。
• Glycoside compound and preparation method therefor, composition, application, and intermediate
  申请人：SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

  公开号：US11325937B2

  公开（公告）日：2022-05-10

  The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

  本发明公开了一种由式 III 表示的糖苷化合物及其制备方法、组合物、用途和中间体。本发明提供的苷类化合物制备方法简单，能显著提高血管内皮生长因子-A mRNA的表达，有效促进血管生成。这为开发治疗脑梗塞脑中风、心肌梗塞、下肢缺血性微循环障碍等具有促血管生成活性的药物提供了可靠保证。